Literature DB >> 8216107

Corticosteroids for the enhancement of fetal lung maturity: impact on the gravida with preeclampsia and the HELLP syndrome.

E F Magann1, R W Martin, J D Isaacs, P G Blake, J C Morrison, J N Martin.   

Abstract

This study was undertaken to determine maternal impact of corticosteroids administered for the promotion of fetal lung maturity in mothers with the HELLP syndrome. Twenty-seven of 427 women with the HELLP syndrome treated between 1980-1991 received a full course of steroids prior to preterm delivery. This group was compared to 27 matched control patients with the HELLP syndrome who received no corticosteroids. Subjects were matched for maternal age, race, sex of the fetus, and severity of the HELLP syndrome. The antepartum platelet count stabilized or increased in 25 of 27 steroid-treated women in contrast to 0 of 15 control women (p < 0.00001). In comparison to control patients, LDH serum concentrations in steroid-treated patients stabilized or decreased and the SGOT/AST and SGPT/ALT stabilized or decreased during therapy (p < 0.005). The interval from delivery to platelet nadir in patients with Class III HELLP syndrome was shorter in the steroid-treated group (p < 0.008) than in untreated patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216107     DOI: 10.1111/j.1479-828x.1993.tb02374.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  2 in total

Review 1.  Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy.

Authors:  Douglas M Woudstra; Sue Chandra; G Justus Hofmeyr; Therese Dowswell
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

Review 2.  Prognostic Factors of the Efficacy of High-dose Corticosteroid Therapy in Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome During Pregnancy: A Meta-analysis.

Authors:  Li Yang; Chenchen Ren; Minhong Mao; Shihong Cui
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.